# Biotech Daily Digest — 2025-10-31

**39 items from 3 sources**

## Summary by Source

- Endpoints News: 13 items
- Fierce Biotech: 7 items
- arXiv q-bio: 19 items


## Endpoints News

- **[What would Metsera bring to Novo Nordisk?](https://endpoints.news/what-would-metsera-bring-to-novo-nordisk/)**  
  _Fri, 31 Oct 2025 11:32:14 +0000_  
  Pfizer’s motivation to buy Metsera is clear: The big pharma wants to plug the hole in its revenues by getting back into obesity, the world’s fastest-growing drug category.

 Novo Nordisk

- **[Post-Hoc Live: Meet the scientists behind Baby KJ’s life-saving CRISPR therapy](https://endpoints.news/post-hoc-live-meet-the-scientists-behind-baby-kjs-life-saving-crispr-therapy/)**  
  _Fri, 31 Oct 2025 11:00:14 +0000_  
  Earlier this year, researchers in Philadelphia announced they’d developed a custom-made therapy to fix one infant’s rare genetic mutation. The news about Baby KJ opened the possibility of a new model for treating ultra-rare genetic ...

- **[Vesper Bio reports early biomarker data for neurodegenerative disease candidate](https://endpoints.news/vesper-bio-reports-early-biomarker-data-for-neurodegenerative-disease-candidate/)**  
  _Fri, 31 Oct 2025 10:57:21 +0000_  
  A Copenhagen-based biotech said its drug candidate has the potential to normalize levels of a key biomarker that is critical in a genetic form of neurodegeneration.

 A Phase 1b/2a trial was run to investigate whether ...

- **[Gilead sees cell therapy sales decline in Q3](https://endpoints.news/gilead-sees-cell-therapy-sales-decline-in-q3/)**  
  _Fri, 31 Oct 2025 01:45:15 +0000_  
  Gilead Sciences said that its cell therapy revenue dropped 11% in the third quarter compared with a year ago, citing lower demand for its two CAR-T cell therapies, Yescarta and Tecartus.

 The light quarter, with ...

- **[Novo’s Metsera offer could pose a test for Trump's FTC](https://endpoints.news/novos-metsera-offer-could-pose-a-test-for-trumps-ftc/)**  
  _Thu, 30 Oct 2025 19:50:23 +0000_  
  Novo Nordisk’s surprise $9 billion offer for obesity drugmaker Metsera could be the first major test of how the Trump administration’s FTC grapples with complex pharmaceutical mergers.

 The bid looks to pit ...

- **[HHS approves 340B rebate model plans for Merck, Bristol Myers and others](https://endpoints.news/hhs-approves-340b-rebate-model-plans-for-merck-bristol-myers-and-others/)**  
  _Thu, 30 Oct 2025 19:47:44 +0000_  
  HHS has approved applications from eight drugmakers to participate in the government’s pilot program testing a rebate model for certain 340B discounts.

 The green light from HHS’ Health Resources and Services ...

- **[Lilly CEO expects more 'noise' as Metsera M&A fight begins](https://endpoints.news/lilly-ceo-expects-more-noise-as-metsera-ma-fight-begins/)**  
  _Thu, 30 Oct 2025 19:32:53 +0000_  
  Despite boasting a $1.5 billion sales beat, Eli Lilly’s earnings were overshadowed by its top competitor Novo Nordisk's efforts to usurp Pfizer in a bidding war over clinical-stage obesity biotech Metsera.

 Responding to questions from ...

- **[Merck CEO touts Winrevair launch, says he’s looking for deals ‘with urgency’](https://endpoints.news/merck-ceo-touts-winrevair-launch-says-hes-looking-for-deals-with-urgency/)**  
  _Thu, 30 Oct 2025 18:49:30 +0000_  
  Merck CEO Rob Davis said on Thursday that the company is assessing ways to bring in new assets “with urgency.”

 The comments signal Merck’s continued appetite for deals as the company bolsters its pipeline ahead ...

- **[Post-Hoc Live: Breaking down the M&A drama between Pfizer, Metsera and Novo](https://endpoints.news/post-hoc-live-breaking-down-the-ma-drama-between-pfizer-metsera-and-novo/)**  
  _Thu, 30 Oct 2025 17:06:04 +0000_  
  The obesity wars just got spicier.

 Today, just a month after Pfizer said it would buy Metsera, Novo Nordisk swooped in with its own bid. Metsera says Novo’s offer is “superior.” Pfizer ...

- **[National Resilience secures $825M in funding; Regeneron details US manufacturing plans](https://endpoints.news/national-resilience-secures-825m-in-funding-regeneron-details-us-manufacturing-plans/)**  
  _Thu, 30 Oct 2025 15:34:59 +0000_  
  Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more.

 National Resilience has secured $825 million in debt financing from Oak Hill ...

- **[The showdown over Metsera: Pfizer and Novo prepare for a bidding war](https://endpoints.news/the-showdown-over-metsera-pfizer-and-novo-prepare-for-a-bidding-war/)**  
  _Thu, 30 Oct 2025 15:20:13 +0000_  
  Two of the biggest drug companies in the world are preparing for a multibillion-dollar showdown to buy Metsera, after Novo Nordisk’s shock announcement Thursday that it had offered $1.6 billion more than ...

- **[Tectonic shares rise on back of Phase 1 heart failure data](https://endpoints.news/tectonic-shares-buoy-on-back-of-phase-1-heart-failure-data/)**  
  _Thu, 30 Oct 2025 15:18:52 +0000_  
  Tectonic Therapeutic shares rose 16% Thursday morning after the biotech shared positive early-stage data from its drug candidate in certain patients with heart failure.

 The company’s asset, called TX45, achieved “meaningful improvements” in 14 patients ...

- **[Novo Nordisk’s new CEO is chasing the deals its former leaders wouldn't](https://endpoints.news/novo-nordisks-new-ceo-is-chasing-the-deals-its-former-leaders-wouldnt/)**  
  _Thu, 30 Oct 2025 15:12:24 +0000_  
  Novo Nordisk brought on Maziar Mike Doustdar as CEO to make sweeping changes at the company, which is struggling to claw back the ground it's lost to Eli Lilly in the obesity market.

 On Thursday ...


## Fierce Biotech

- **[<a href="https://www.fiercebiotech.com/medtech/illumina-sales-flat-q3-amid-china-headwinds-ceo-remains-dialogue-agencies" hreflang="en">Illumina sales flat in Q3 amid China headwinds as CEO remains 'in dialogue' with agencies</a>](https://www.fiercebiotech.com/medtech/illumina-sales-flat-q3-amid-china-headwinds-ceo-remains-dialogue-agencies)**  
  _Oct 31, 2025 2:50am_  
  Illumina’s revenue was flat for the third quarter as the sequencing giant continues to deal with headwinds from a China sales ban.

- **[<a href="https://www.fiercebiotech.com/biotech/cash-strapped-nanobiotix-finds-fresh-way-source-cash-jj-partnered-cancer-drug" hreflang="en">Cash-strapped Nanobiotix finds fresh way to source cash from J&amp;J-partnered cancer drug</a>](https://www.fiercebiotech.com/biotech/cash-strapped-nanobiotix-finds-fresh-way-source-cash-jj-partnered-cancer-drug)**  
  _Oct 31, 2025 6:08am_  
  Nanobiotix is continuing to find fresh ways to eke money out of its Johnson & Johnson-partnered, phase 3-stage cancer drug.

- **[<a href="https://www.fiercebiotech.com/biotech/4dmt-eyes-385m-deal-otsuka-cash-aimed-retinal-gene-therapys-phase-3-plans" hreflang="en">4DMT eyes $420M deal from Otsuka, with cash aimed at retinal gene therapy's phase 3 plans</a>](https://www.fiercebiotech.com/biotech/4dmt-eyes-385m-deal-otsuka-cash-aimed-retinal-gene-therapys-phase-3-plans)**  
  _Oct 31, 2025 5:13am_  
  4DMT has sold the Asia-Pacific rights to its eye gene therapy to Otsuka Pharmaceutical, securing $85 million in cash to fund the asset’s phase 3 development.

- **[<a href="https://www.fiercebiotech.com/biotech/gilead-ends-ph-1-trial-after-settling-twice-yearly-treatment-partner-lenacapavir" hreflang="en">Gilead ends phase 1 trial after settling on twice-yearly treatment partner for lenacapavir</a>](https://www.fiercebiotech.com/biotech/gilead-ends-ph-1-trial-after-settling-twice-yearly-treatment-partner-lenacapavir)**  
  _Oct 30, 2025 6:39pm_  
  Gilead has chosen a partner for lenacapavir in the race to develop low-frequency treatments for HIV. After comparing two phase 1 integrase strand transfer inhibitors, the Bay Area pharma has elected to pair GS-3242 with lenacapavir moving forward and not GS-1219, Gilead announced during its third quarter earnings call…

- **[<a href="https://www.fiercebiotech.com/biotech/eli-lilly-sidelines-midstage-pain-prospect-another-pipeline-shift" hreflang="en">Eli Lilly sidelines midstage prospect in another pain pipeline pivot</a>](https://www.fiercebiotech.com/biotech/eli-lilly-sidelines-midstage-pain-prospect-another-pipeline-shift)**  
  _Oct 30, 2025 1:28pm_  
  Eli Lilly has halted development of a phase 2 P2X7 inhibitor for pain in the latest shakeup to a pipeline that has already seen significant pivots this year.

- **[<a href="https://www.fiercebiotech.com/biotech/bms-culls-2-clinical-programs-one-mirati-and-another-exscientia" hreflang="en">BMS removes 2 clinical programs from pipeline, one from Mirati and another from Exscientia</a>](https://www.fiercebiotech.com/biotech/bms-culls-2-clinical-programs-one-mirati-and-another-exscientia)**  
  _Oct 30, 2025 12:38pm_  
  Bristol Myers Squibb is shedding two clinical programs from its in-house pipeline, one from its 2023 Mirati buyout and another from a partnership with U.K. biotech Exscientia, now known as Recursion.

- **[<a href="https://www.fiercebiotech.com/biotech/inflammation-biotech-evommune-prices-ipo-after-maplights-250m-debut" hreflang="en">Inflammation biotech Evommune prices IPO after MapLight's $250M debut</a>](https://www.fiercebiotech.com/biotech/inflammation-biotech-evommune-prices-ipo-after-maplights-250m-debut)**  
  _Oct 30, 2025 12:17pm_  
  Inflammation biotech Evommune plans to take the leap into public waters with an expected initial public offering price between $15 and $17 per share.


## arXiv q-bio

- **[Evaluating the effectiveness of Stochastic CTMC and deterministic models in correlating rabies persistence in human and dog populations](https://arxiv.org/abs/2510.25777)**  
  _Fri, 31 Oct 2025 00:00:00 -0400_  
  arXiv:2510.25777v1 Announce Type: new 
Abstract: Rabies continues to pose a significant zoonotic threat, particularly in areas with high populations of domestic dogs that serve as viral reservoirs. This study conducts a comparative analysis of Stochastic Continuous-Time Markov Chain (CTMC) and deterministic models to…

- **[Integrated Multi-omics Reveals MEF2C as a Direct Regulator of Microglial Immune and Synaptic Programs](https://arxiv.org/abs/2510.25780)**  
  _Fri, 31 Oct 2025 00:00:00 -0400_  
  arXiv:2510.25780v1 Announce Type: new 
Abstract: Background: Patients carrying MEF2C haploinsufficiency develop a recognizable neurodevelopmental syndrome featuring intellectual disability, treatment-resistant seizures, and autism spectrum behaviors. While MEF2C's critical roles in cardiac development and neuronal fun…

- **[Discovering Interpretable Biological Concepts in Single-cell RNA-seq Foundation Models](https://arxiv.org/abs/2510.25807)**  
  _Fri, 31 Oct 2025 00:00:00 -0400_  
  arXiv:2510.25807v1 Announce Type: new 
Abstract: Single-cell RNA-seq foundation models achieve strong performance on downstream tasks but remain black boxes, limiting their utility for biological discovery. Recent work has shown that sparse dictionary learning can extract concepts from deep learning models, with promi…

- **[Optimizing Mirror-Image Peptide Sequence Design for Data Storage via Peptide Bond Cleavage Prediction](https://arxiv.org/abs/2510.25814)**  
  _Fri, 31 Oct 2025 00:00:00 -0400_  
  arXiv:2510.25814v1 Announce Type: new 
Abstract: Traditional non-biological storage media, such as hard drives, face limitations in both storage density and lifespan due to the rapid growth of data in the big data era. Mirror-image peptides composed of D-amino acids have emerged as a promising biological storage mediu…

- **[InputDSA: Demixing then Comparing Recurrent and Externally Driven Dynamics](https://arxiv.org/abs/2510.25943)**  
  _Fri, 31 Oct 2025 00:00:00 -0400_  
  arXiv:2510.25943v1 Announce Type: new 
Abstract: In control problems and basic scientific modeling, it is important to compare observations with dynamical simulations. For example, comparing two neural systems can shed light on the nature of emergent computations in the brain and deep neural networks. Recently, Ostrow…

- **[Integrated Information Theory: A Consciousness-First Approach to What Exists](https://arxiv.org/abs/2510.25998)**  
  _Fri, 31 Oct 2025 00:00:00 -0400_  
  arXiv:2510.25998v1 Announce Type: new 
Abstract: This overview of integrated information theory (IIT) emphasizes IIT's "consciousness-first" approach to what exists. Consciousness demonstrates to each of us that something exists--experience--and reveals its essential properties--the axioms of phenomenal existence. IIT…

- **[Biological Engineering: What does it mean? Where does it - need to - go?](https://arxiv.org/abs/2510.26525)**  
  _Fri, 31 Oct 2025 00:00:00 -0400_  
  arXiv:2510.26525v1 Announce Type: new 
Abstract: Biological engineering, the convergence between engineering and biology, is at the forefront of significant advances in healthcare, agriculture, and environmental sustainability, making it highly relevant to current scientific and societal challenges. We take a comprehe…

- **[A Proposed Framework for Quantifying AI-to-Clinical Translation: The Algorithm-to-Outcome Concordance (AOC) Metric](https://arxiv.org/abs/2510.26685)**  
  _Fri, 31 Oct 2025 00:00:00 -0400_  
  arXiv:2510.26685v1 Announce Type: new 
Abstract: Background: The rapid evolution of personalized neoantigen vaccines has been accelerated by artificial intelligence (AI)-based prediction models. Yet, a consistent framework to evaluate the translational fidelity between computational predictions and clinical outcomes r…

- **[Modelling ion channels with a view towards identifiability](https://arxiv.org/abs/2510.26728)**  
  _Fri, 31 Oct 2025 00:00:00 -0400_  
  arXiv:2510.26728v1 Announce Type: new 
Abstract: Aggregated Markov models provide a flexible framework for stochastic dynamics that develops on multiple timescales. For example, Markov models for ion channels often consist of multiple open and closed state to account for "slow" and "fast" openings and closings of the…

- **[Brain-IT: Image Reconstruction from fMRI via Brain-Interaction Transformer](https://arxiv.org/abs/2510.25976)**  
  _Fri, 31 Oct 2025 00:00:00 -0400_  
  arXiv:2510.25976v1 Announce Type: cross 
Abstract: Reconstructing images seen by people from their fMRI brain recordings provides a non-invasive window into the human brain. Despite recent progress enabled by diffusion models, current methods often lack faithfulness to the actual seen images. We present "Brain-IT", a…

- **[Quenched coalescent for diploid population models with selfing and overlapping generations](https://arxiv.org/abs/2510.26115)**  
  _Fri, 31 Oct 2025 00:00:00 -0400_  
  arXiv:2510.26115v1 Announce Type: cross 
Abstract: We introduce a general diploid population model with self-fertilization and possible overlapping generations, and study the genealogy of a sample of $n$ genes as the population size $N$ tends to infinity. Unlike traditional approach in coalescent theory which consider…

- **[On the number of non-degenerate canalizing Boolean functions](https://arxiv.org/abs/2510.26556)**  
  _Fri, 31 Oct 2025 00:00:00 -0400_  
  arXiv:2510.26556v1 Announce Type: cross 
Abstract: Canalization is a key organizing principle in complex systems, particularly in gene regulatory networks. It describes how certain input variables exert dominant control over a function's output, thereby imposing hierarchical structure and conferring robustness to pert…

- **[Integrating Protein Sequence and Expression Level to Analysis Molecular Characterization of Breast Cancer Subtypes](https://arxiv.org/abs/2410.01755)**  
  _Fri, 31 Oct 2025 00:00:00 -0400_  
  arXiv:2410.01755v3 Announce Type: replace 
Abstract: Breast cancer's complexity and variability pose significant challenges in understanding its progression and guiding effective treatment. This study aims to integrate protein sequence data with expression levels to improve the molecular characterization of breast can…

- **[Modeling Neural Activity with Conditionally Linear Dynamical Systems](https://arxiv.org/abs/2502.18347)**  
  _Fri, 31 Oct 2025 00:00:00 -0400_  
  arXiv:2502.18347v2 Announce Type: replace 
Abstract: Neural population activity exhibits complex, nonlinear dynamics, varying in time, over trials, and across experimental conditions. Here, we develop Conditionally Linear Dynamical System (CLDS) models as a general-purpose method to characterize these dynamics. These…

- **[UniSite: The First Cross-Structure Dataset and Learning Framework for End-to-End Ligand Binding Site Detection](https://arxiv.org/abs/2506.03237)**  
  _Fri, 31 Oct 2025 00:00:00 -0400_  
  arXiv:2506.03237v2 Announce Type: replace 
Abstract: The detection of ligand binding sites for proteins is a fundamental step in Structure-Based Drug Design. Despite notable advances in recent years, existing methods, datasets, and evaluation metrics are confronted with several key challenges: (1) current datasets and…

- **[Low dimensional dynamics of a sparse balanced synaptic network of quadratic integrate-and-fire neurons](https://arxiv.org/abs/2508.06253)**  
  _Fri, 31 Oct 2025 00:00:00 -0400_  
  arXiv:2508.06253v2 Announce Type: replace 
Abstract: Kinetics of a balanced network of neurons with a sparse grid of synaptic links is well representable by the stochastic dynamics of a generic neuron subject to an effective shot noise. The rate of delta-pulses of the noise is determined self-consistently from the pro…

- **[A Continuous and Interpretable Morphometric for Robust Quantification of Dynamic Biological Shapes](https://arxiv.org/abs/2410.21004)**  
  _Fri, 31 Oct 2025 00:00:00 -0400_  
  arXiv:2410.21004v2 Announce Type: replace-cross 
Abstract: We introduce the Push-Forward Signed Distance Morphometric (PF-SDM) for shape quantification in biomedical imaging. The PF-SDM compactly encodes geometric and topological properties of closed shapes, including their skeleton and symmetries. This provides robus…

- **[AANet: Virtual Screening under Structural Uncertainty via Alignment and Aggregation](https://arxiv.org/abs/2506.05768)**  
  _Fri, 31 Oct 2025 00:00:00 -0400_  
  arXiv:2506.05768v2 Announce Type: replace-cross 
Abstract: Virtual screening (VS) is a critical component of modern drug discovery, yet most existing methods--whether physics-based or deep learning-based--are developed around holo protein structures with known ligand-bound pockets. Consequently, their performance degr…

- **[Multiscale Growth Kinetics of Model Biomolecular Condensates Under Passive and Active Conditions](https://arxiv.org/abs/2508.16398)**  
  _Fri, 31 Oct 2025 00:00:00 -0400_  
  arXiv:2508.16398v2 Announce Type: replace-cross 
Abstract: Living cells exhibit a complex organization comprising numerous compartments, among which are RNA- and protein-rich membraneless, liquid-like organelles known as biomolecular condensates. Energy-consuming processes regulate their formation and dissolution, wit…
